Toll Interacting Protein (TOLLIP) Antibody

Documentos del producto

Especificaciones del producto

Primary Antibodies

Target: Toll Interacting Protein (TOLLIP)

Rabbit

Human

Concentration: 1 mg/ml

Validated in IHC-P and IHC-F. Optimal dilutions/concentrations should be determined by the end user.

Polyclonal

Unconjugated

Purified by affinity chromatography using epitope-specific immunogen.

50 µg

100 µg

Liquid

ELISA, WB, IHC, IF/ICC

PBS, pH 7.4, containing 0.02% sodium azide and 50% glycerol.

Shipped within 5-12 working days.

Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles.

No

Q9H0E2

TOLLIP, IL-1RAcPIP, toll interacting protein

Antibody anti-TOLLIP

RUO

THIS PRODUCT IS FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC, THERAPEUTIC OR COSMETIC PROCEDURES. NOT FOR HUMAN OR ANIMAL CONSUMPTION.

Background

TOLLIP is a negative regulator of Toll-like receptor (TLR) signaling, controlling inflammatory responses by inhibiting downstream activation of NF-κB and MAPK pathways. It functions as an adaptor protein that binds to TLRs and signaling intermediates, such as IRAK1 and TRAF6, to dampen excessive cytokine production and inflammatory responses during pathogen recognition. TOLLIP also plays a role in endosomal trafficking and autophagy, regulating receptor turnover and degradation to maintain immune homeostasis. It is widely expressed in immune cells, epithelial tissues, and organs like the liver and lungs, where it prevents chronic inflammation and excessive immune activation. Dysregulation or reduced expression of TOLLIP is associated with inflammatory diseases, autoimmune disorders, and increased susceptibility to infections. Knockdown studies reveal hyperactivated TLR signaling, elevated cytokine production, and impaired immune tolerance, highlighting its role as a key regulator of TLR signaling, inflammation, and immune homeostasis.